EUVIMEDEUVIMED entdecken
Open Access

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells

Waseem Qasim iD

Blood · 23.02.2023 · 141 (8) · 835-845

DOI: 10.1182/blood.2022016204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 23.02.2023. Verfasst von Waseem Qasim. Beteiligte Einrichtung: UCL Great Ormond Street Institute of Child Health, Zayed Centre for Research, London, United Kingdom. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

αβ T cell receptor (TCRαβ) T cells modified to express chimeric antigen receptors (CAR), are now available as authorized therapies for certain B-cell malignancies. However the process of autologous harvest and generation of patient-specific products is costly, with complex logistics and infrastructure requirements. Premanufactured banks of allogeneic donor–derived CAR T cells could help widen applicability if the challenges of HLA-mismatched T-cell therapy can be addressed. Genome editing is being applied to overcome allogeneic barriers, most notably, by disrupting TCRαβ to prevent graft-versus-host disease, and multiple competing editing technologies, including CRISPR/Cas9 and base editing, have reached clinical phase testing. Improvements in accuracy and efficiency have unlocked applications for a wider range of blood malignancies, with multiplexed editing incorporated to target HLA molecules, shared antigens and checkpoint pathways. Clinical trials will help establish safety profiles and determine the durability of responses as well as the role of consolidation with allogeneic transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHematopoietic Stem Cell TransplantationHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellT-LymphocytesGene EditingReceptors, Antigen, T-Cell, alpha-beta

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-CellReceptors, Antigen, T-Cell, alpha-beta

Autor:innen und Institutionen

  • UCL Great Ormond Street Institute of Child Health, Zayed Centre for Research, London, United Kingdom.

ORCID-Profile: Waseem Qasim

Förderung

  • Wellcome Trust

Zitieren

APA

Qasim, W. (2023). Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells. Blood, 141(8), 835-845. https://doi.org/10.1182/blood.2022016204

Vancouver

Qasim W. Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells. Blood. 2023;141(8):835-845. doi:10.1182/blood.2022016204

BibTeX
@article{Qasim2023,
  author = {Qasim, Waseem},
  title = {Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {8},
  pages = {835--845},
  doi = {10.1182/blood.2022016204}
}
Kostenlos starten →